A Prototype Study to Test the Effect of Staggered Dosing on the Pharmacokinetic Interactions Between Paired Combinations of Nelfinavir (NFV), Ritonavir (RTV), and Soft Gelatin Capsule of Saquinavir (SQVsgc)

Inclusion Criteria Patients must have: Absence of HIV-1 infection as documented by any licensed ELISA test kit within 14 days prior to study entry. Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: Any medical condition that, in the opinion of the investigator, would interfere with the patient's ability to participate in this protocol. Patients with the following prior conditions and symptoms are excluded: History of chronic illness such as hypertension, coronary artery disease, arthritis, diabetes, or any chronic gastrointestinal conditions that might interfere with drug absorption.